Skip to main content
Premium Trial:

Request an Annual Quote

TriCore Named Life Tech Regional NGS Center of Excellence

NEW YORK (GenomeWeb News) – Life Technologies and TriCore Reference Laboratories will collaborate to establish TriCore as a regional Next Generation Sequencing Center of Excellence, Life Tech said today.

The agreement is part of Life Tech's initiative to establish a global alliance of centers running next-gen sequencing-based oncology panels for clinical research.

As part of the agreement, TriCore, a not-for-profit medical reference laboratory, will provide Life Tech's next-gen oncology panels, including the Ion AmpliSeq panels that run on the Ion Torrent PGM and Ion Proton sequencing systems, to clinical researchers.

Albuquerque, NM-based TriCore will also work with the pathology department at the University of New Mexico Health Sciences Center.

"This alliance fits with TriCore's commitment to oncology services and will allow us to provide greater value to our clients," Michael Crossey, TriCore's interim CEO and executive medical director, said in a statement. "The results we generate through next-generation sequencing will be used to elucidate new drug targets with the potential to guide therapeutic options more efficiently in the future."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.